← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Nucleosides and nucleotides excl. reverse transcriptase inhibitors
brincidofovir
J05AB17
Forms & Strengths
- Oral suspension: 10 mg/mL
- Tablet: 100 mg
Adult Dosing
- Smallpox: 200 mg orally once weekly for 2 doses (Day 1 and Day 8)
Pediatric Dosing
- Weight-based dosing for pediatric patients weighing >= 48 kg: 200 mg orally once weekly for 2 doses
- Weight-based dosing for pediatric patients weighing 10 kg to < 48 kg: 6 mg/kg orally once weekly for 2 doses
- Weight-based dosing for pediatric patients weighing < 10 kg: 2.1 mg/kg orally twice weekly for 2 weeks
Indications
- Treatment of human smallpox disease causedr by variola virus in adult and pediatric patients of all ages
Mechanism of Action
- Lipid conjugate of cidofovir that acts as an antiviral agent
- Intracellularly converted to cidofovir diphosphate, which selectively inhibits orthopoxvirus DNA polymerase and terminates viral DNA chain elongation
Contraindications
- Known hypersensitivity to brincidofovir or any of its components
Adverse Reactions
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Elevated transaminases and serum creatinine
Drug Interactions
- Substrate of organic anion transporting polypeptides (OATP) 1B1 and 1B3
- Concomitant use with strong OATP1B1 and 1B3 inhibitors may increase systemic exposure of brincidofovir
Curated Content: Needs Vetting Before Put to Clinical Use